Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kim Forest Enterprise CoTPE:6645 -3.88%58 Debt-to-Equity is 1.14 as of Jun. 2026, which is 115% above its 10-year median of 0.53. GuruFocus rates TPE:6645 with a GF Score™ of 58/100 and a GF Value™ of NT$24.68 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 180 Medical Diagnostics & Research companies, Kim Forest Enterprise Co ranks worse than 85% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kim Forest Enterprise Co's Debt-to-Equity or its related term are showing as below:
TPE:6645'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.53 Max: 1.14
Current: 1.14
During the past 13 years, the highest Debt-to-Equity Ratio of Kim Forest Enterprise Co was 1.14. The lowest was 0.12. And the median was 0.53.
TPE:6645's Debt-to-Equity is ranked worse than 85% of 180
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.275
vs TPE:6645: 1.14
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kim Forest Enterprise Co Debt-to-Equity Related Terms
Kim Forest Enterprise Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6645 vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Kim Forest Enterprise Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kim Forest Enterprise Co Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Kim Forest Enterprise Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kim Forest Enterprise Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kim Forest Enterprise Co (TPE:6645) has a Debt-to-Equity of 1.14 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kim Forest Enterprise Co and its competitors. This is 115% above median its historical median of 0.53. Over the past decade, Kim Forest Enterprise Co's Debt-to-Equity has ranged from 0.12 to 1.14. According to the industry distribution chart, Kim Forest Enterprise Co ranks #153 out of 180 companies in the Medical Diagnostics & Research industry, placing it in the top 85%.
Is Kim Forest Enterprise Co's Debt-to-Equity too high?
Kim Forest Enterprise Co's current Debt-to-Equity of 1.14 is 115% above median its 10-year median of 0.53. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 1.14. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.28. Kim Forest Enterprise Co's value of 1.14 is 314.5% above this industry median. Based on the distribution chart, Kim Forest Enterprise Co ranks #153 out of 180 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Kim Forest Enterprise Co has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kim Forest Enterprise Co's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Kim Forest Enterprise Co ranks #153 out of 180 companies for Debt-to-Equity. This places Kim Forest Enterprise Co in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Kim Forest Enterprise Co's value of 1.14 is 314.5% above this benchmark. Historically, Kim Forest Enterprise Co's own Debt-to-Equity has ranged from 0.12 to 1.14 over the past decade. While the company's 10-year median is 0.53 vs. the industry median of 0.28, Kim Forest Enterprise Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.28, based on 180 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kim Forest Enterprise Co's current Debt-to-Equity of 1.14 is 314.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kim Forest Enterprise Co and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kim Forest Enterprise Co's current Debt-to-Equity is 1.14, which is 115% above median its own 10-year median of 0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kim Forest Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Kim Forest Enterprise Co (TPE:6645) is currently considered Possible Value Trap. The stock's GF Value™ is NT$24.68, compared to a current price of NT$12.40 — trading 49.8% below its estimated fair value. The current Debt-to-Equity is 1.14, which is 115% above median its 10-year median of 0.53 and 314.5% above the Medical Diagnostics & Research industry median of 0.28. Kim Forest Enterprise Co's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kim Forest Enterprise Co (TPE:6645), the current Debt-to-Equity is 1.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kim Forest Enterprise Co (TPE:6645) Overvalued in 2026?
Based on GuruFocus' analysis, Kim Forest Enterprise Co stock appears to be undervalued.
The current stock price of NT$12.40 is trading 49.8% below its estimated GF Value™ of NT$24.68.
GuruFocus considers Kim Forest Enterprise Co to be Possible Value Trap.
Key valuation signals for TPE:6645:
Debt-to-Equity: 1.14 (115% above median its 10-year median of 0.53)
GF Value™: NT$24.68 vs. price of NT$12.40 (49.8% below fair value)
Industry Position: 314.5% above the Medical Diagnostics & Research median (#153 of 180)
No single metric tells the full story. See the TPE:6645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kim Forest Enterprise Co Ltd is engaged in providing clinical medical information, genetic testing services, and biological information. It manufactures medical equipment and also produces drug products. The company's equipment includes Desktop microcentrifuge, Desktop large capacity centrifuge, Filter-type absorption spectrometer, Multifunctional spectrometer, and many more. Its reportable segments are Biomedical products which generates key revenue, and the Precision medicine segment. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the United States of America.
58GF Score
Get the complete analysis for TPE:6645
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6645 has been successfully added to your 
